Vincenzo Di Nicola
Investment Banking
LONDON, 22 OCTOBER 2024 – Bryan, Garnier & Co, the leading investment bank for healthcare and technology-related companies, today announces that Vincenzo Di Nicola has been appointed as a Partner in the healthcare team. He will continue to strengthen the bank’s European and US healthcare practice from the London and New York office.
Vincenzo has over 20 years of investment banking experience predominantly focused on transatlantic healthcare transactions and with a track record of building teams. He joins from Piper Sandler where he was Global Head of Pharma Services and Co-Head of European Healthcare. Before that, he was Co-Head of Pharma Services and European Head of Healthcare at Cantor Fitzgerald.
Vincenzo earned a Bachelor’s degree in International Economics from the University of Naples and a Master’s in Finance from the London Business School.
Hervé Ronin, Partner and Head of Global Healthcare said: “We are delighted to welcome Vincenzo, who will be a great asset to the London team as we look to keep growing our pan-European healthcare capabilities. His appointment, on the back of the recent goetzpartners hires, will enhance our advisory expertise to leading international and transatlantic companies.”
Vincenzo Di Nicola added: “I am very excited to be part of the Bryan Garnier healthcare team. The bank has become a leader in Life Sciences, advising on a number of high-profile M&A, financings and IPO transactions in the sector, and I know that they have ambitious plans for future growth. I am looking forward to using my expertise to help the bank further deepen its healthcare services.”
With offices in Europe and the US, Bryan, Garnier & Co has established itself as one of the most active investment banks in pan-European growth financing via the public and private markets.
Advising healthcare companies has been one of the investment bank’s core competencies for decades, including advising RNA pioneers Moderna and BioNTech on several financing rounds and IPOs, and most recently advising vaccine group Valneva as Joint Global Coordinator and Joint Bookrunner on its Euronext capital increase.
Bryan Garnier’s holistic approach to advising clients on the full range of equity, debt and M&A transactions creates a true client-first model, building long-term relationships over the full business lifecycle. As a sector-focused bank since inception, Bryan Garnier specialises in Healthcare, Software & Fintech, Energy Transition and Sustainability, Industrial Tech, Business and Tech-Enabled Services and NextGen Consumer. Bryan Garnier’s mission of investment banking for a better future continues to drive the firm as it backs innovative companies and their investors that are providing solutions to some of the world’s most important challenges.
About Bryan, Garnier & Co
Bryan, Garnier’s is a European growth investment bank helping companies in the healthcare and technology related sectors become global champions. By combining deep sector expertise with an entrepreneurial mindset, Bryan Garnier provides companies and their investors with independent growth strategic advice, and leading access to buyers and capital in Europe, US and Asia
As a full-service investment bank, the firm offering includes private and public growth financing solutions, mergers and acquisitions (M&A) advisory, research insights, and institutional sales & execution. Founded in 1996, Bryan, Garnier & Co is an independent partnership with around 200 employees located in major financial centres in Europe and the US.